/
DCF Valuation
Base-case fair value
$139.89
Intrinsic $186.52 · 25% MOS
Base-case summary
Our base-case DCF for Alnylam Pharmaceuticals, Inc. (ALNY) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 123.0% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $465M in trailing free cash flow, this produces an intrinsic value of $186.52 per share. A 25% safety margin gives a fair value of $139.89.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$465M
Cash & equivalents
$2.9B
Total debt
$1.3B
Shares outstanding
135M